Table 1.
Baseline patient characteristics.
| Charateristic | N (total = 152) | % |
|---|---|---|
| Sex | ||
| Female | 60 | 39.5 |
| Male | 92 | 60.5 |
| Median age, years (IQR 25-75%) | 66 (58-72) | |
| Ethnicity | ||
| Caucasian | 128 | 84.2 |
| Mixed race | 1 | 0.7 |
| Asian | 10 | 6.6 |
| African | 2 | 1.3 |
| Caribbean | 3 | 2.0 |
| Oriental | 2 | 1.3 |
| Other | 6 | 4.0 |
| Anatomical site of malignancy | ||
| Colorectal | 80 | 52.6 |
| Oesophagogastric | 38 | 25.0 |
| Hepato pancreatic and biliary | 24 | 15.8 |
| Other* | 10 | 6.6 |
| Cancer stage | ||
| Early | 54 | 35.5 |
| Advanced | 98 | 64.5 |
| Comorbidities | ||
| Cardiovascular disease** | 53 | 34.9 |
| Diabetes | 26 | 17.1 |
| Venous thromboembolism | 10 | 6.6 |
| Asthma/COPD | 10 | 3.9 |
| Chronic liver disease | 4 | 2.6 |
| Autoimmune disorder | 3 | 2.0 |
| Obesity | 2 | 1.3 |
| Chronic kidney disease | 1 | 0.7 |
| Current anticancer therapy | ||
| Systemic therapy | 151 | 99.3 |
| Chemotherapy singlet | 18 | 11.8 |
| Chemotherapy doublet | 81 | 53.9 |
| Chemotherapy doublet + anti PD1/PDL1 | 2 | 1.3 |
| Chemotherapy triplet | 14 | 9.2 |
| Chemotherapy triplet + anti PD1/PDL1 | 7 | 4.6 |
| Chemotherapy with radiotherapy | 9 | 5.9 |
| Anti-PD1/PDL1 | 13 | 8.6 |
| Other targeted therapy*** | 7 | 4.6 |
Includes 3 patients with Non-Hodgkin Lymphoma, 3 patients with carcinoma of unknown primary, 2 patients with anal cancer, and 1 patient each with appendiceal cancer and neuroendocrine carcinoma.
Includes hypertension, heart failure, ischaemic heart disease, and cerebrovascular disease.
Includes 2 patients receiving olaparib and 1 patient each receiving lanreotide, derazantinib, ramucirumab, rituximab, trastuzumab deruxtecan.